Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study.

BACKGROUND Interleukin-2 is an important regulatory cytokine of the immune system, with potent effects on T cells, B cells, and natural killer cells. In vitro, interleukin-2 can induce the proliferation and differentiation of peripheral-blood mononuclear cells from patients infected with the human immunodeficiency virus (HIV). METHODS We treated 25 HIV-infected patients with interleukin-2 administered as a continuous infusion at a dosage of 6 to 18 million IU per day for 5 days every 8 weeks during a period of 7 to 25 months. All patients also received at least one approved antiviral agent. Immunologic and virologic variables were monitored monthly. RESULTS In 6 of 10 patients with base-line CD4 counts higher than 200 per cubic millimeter, interleukin-2 therapy was associated with at least a 50 percent increase in the number of CD4 cells. Changes ranged from -81 to +2211 cells per cubic millimeter. Interleukin-2 therapy resulted in a decline in the percentage of CD8 lymphocytes expressing HLA-DR and an increase in the percentage of CD4 lymphocytes that were positive for the p55 chain of the interleukin-2 receptor. Four patients had a transient but consistent increase in the plasma HIV RNA level at the end of each infusion. In the remaining 15 patients, who had CD4 counts of 200 or fewer cells per cubic millimeter, interleukin-2 therapy was associated with increased viral activation, few immunologic improvements, and substantial toxic effects. CONCLUSIONS Intermittent courses of interleukin-2 can improve some of the immunologic abnormalities associated with HIV infection in patients with more than 200 CD4 cells per cubic millimeter.

[1]  M. Urdea,et al.  Direct and quantitative detection of HIV‐1 RNA in human plasma with a branched DNA signal amplification assay , 1993, AIDS.

[2]  A. Fauci,et al.  Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. , 1983, The Journal of clinical investigation.

[3]  M A Fischl,et al.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[4]  H. Mitsuya,et al.  In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. , 1989, Science.

[5]  J. Kovacs,et al.  Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection. , 1990, Annals of internal medicine.

[6]  D. Stites,et al.  Flow cytometric analysis of lymphocyte phenotypes in AIDS using monoclonal antibodies and simultaneous dual immunofluorescence. , 1986, Clinical immunology and immunopathology.

[7]  S. J. Clark,et al.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. , 1993, Science.

[8]  R. Dewar,et al.  Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. , 1994, The Journal of infectious diseases.

[9]  S. Steinberg,et al.  A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. , 1994, The Journal of infectious diseases.

[10]  D. Richman,et al.  Combination Therapy with Zidovudine and Dideoxycytidine in Patients with Advanced Human Immunodeficiency Virus Infection , 1992, Annals of Internal Medicine.

[11]  S. Rosenberg,et al.  Clinical effects and toxicity of interleukin‐2 in patients with cancer , 1986, Cancer.

[12]  R. Davey,et al.  A phase I study of interferon-alpha 2b in combination with interleukin-2 in patients with human immunodeficiency virus infection. , 1994, The Journal of infectious diseases.

[13]  M. Caligiuri,et al.  Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. , 1993, The Journal of clinical investigation.

[14]  J V Giorgi,et al.  Application of flow cytometry to the study of HIV infection. , 1990, AIDS.

[15]  P. Mazza,et al.  Recombinant interleukin‐2 (rIL‐2) in acquired immune deficiency syndrome (AIDS): Preliminary report in patients with lymphoma associated with HIV infection , 1992, European journal of haematology.

[16]  M. Clerici,et al.  T helper cell immune dysfunction in asymptomatic, HIV-1-seropositive individuals: the role of TH1-TH2 cross-regulation. , 1992, Chemical immunology.

[17]  A. Capron,et al.  Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals , 1992, The Journal of experimental medicine.

[18]  R. Detels,et al.  T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. , 1989, Clinical immunology and immunopathology.

[19]  S. Banks,et al.  Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma. A phase II randomized, placebo-controlled trial. , 1989, Annals of internal medicine.

[20]  D. Venzon,et al.  Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. , 1993, The Journal of clinical investigation.

[21]  G. Kaplan,et al.  Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. , 1993, The Journal of infectious diseases.

[22]  M. Baseler,et al.  ANTI-RETROVIRAL EFFECTS OF INTERFERON-α IN AIDS-ASSOCIATED KAPOSI'S SARCOMA , 1988, The Lancet.

[23]  Kendall A. Smith,et al.  Interleukin-2: inception, impact, and implications. , 1988, Science.

[24]  D. Longo,et al.  Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. , 1985, The American journal of medicine.

[25]  E. Gelmann,et al.  Use of interleukin-2 in patients with acquired immunodeficiency syndrome. , 1984, Journal of biological response modifiers.

[26]  T. Merigan,et al.  Safety and Effects of Interleukin‐2 Plus Zidovudine in Asymptomatic Individuals Infected with Human Immunodeficiency Virus , 1991, Journal of acquired immune deficiency syndromes.

[27]  M. Kimoto,et al.  Antigen-reactive T cell clones. I. Transcomplementing hybrid I-A-region gene products function effectively in antigen presentation , 1980, The Journal of experimental medicine.

[28]  J. Nielsen,et al.  The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. The Scandinavian Isoprinosine Study Group. , 1990, The New England journal of medicine.

[29]  R. Schooley,et al.  Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. , 1989, Annals of internal medicine.

[30]  K. Squires,et al.  Interleukin-2 treatment, interferon-γ induction, and AIDS monocyte activation , 1992 .

[31]  P. Dietrich,et al.  Influence of interleukin‐2 administration on the expression of T‐cell receptor V gene segments in patients with renal‐cell carcinoma , 1993, International journal of cancer.

[32]  H. Lane,et al.  Participation of tyrosine phosphorylation in the cytopathic effect of human immunodeficiency virus-1. , 1992, Science.

[33]  A. Capron,et al.  CD3‐mediated apoptosis of human medullary thymocytes and activated peripheral T cells: Respective roles of interleukin‐1, interleukin‐2, interferon‐γ and accessory cells , 1993, European journal of immunology.

[34]  R. Puri,et al.  Interleukin-2 toxicity. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  C. Trépo,et al.  RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF DITIOCARB SODIUM ('IMUTHIOL') IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION , 1988, The Lancet.

[36]  R. Dewar,et al.  Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[37]  G. Kaplan,et al.  Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection , 1993, The Journal of experimental medicine.

[38]  P. Volberding,et al.  Therapy of acquired immune deficiency syndrome with recombinant interleukin-2. , 1987, AIDS research and human retroviruses.

[39]  J. Fahey,et al.  Elevated IFN-gamma and decreased IL-2 gene expression are associated with HIV infection. , 1993, Journal of immunology.

[40]  J. Metcalf,et al.  Interferon-α in patients with asymptomatic human immunodeficiency virus (HIV) infection. , 1990 .